Cargando…
Novel Therapies and Approaches to Relapsed/Refractory HL Beyond Chemotherapy
Although Hodgkin lymphoma (HL) is highly curable with first-line therapy, relapses occur in approximately 10–20% of patients with early stage disease and 30–40% of patients with advanced stage disease. The standard approach for relapsed or refractory disease is salvage therapy, followed by consolida...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468730/ https://www.ncbi.nlm.nih.gov/pubmed/30934568 http://dx.doi.org/10.3390/cancers11030421 |